Imaging Discordance Between [⁶⁸Ga]-PSMA PET and [¹⁷⁷Lu]-PSMA SPECT in mCRPC.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 41474760.
- Also identified by DOI 10.1097/RLU.0000000000006293.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
PSMA PET/CT is commonly used for selecting candidates for [¹⁷⁷Lu]-PSMA radioligand therapy (LuPSMA RLT). However, discrepancies may occur due to pharmacokinetic and biodistribution differences between [⁶⁸Ga]-PSMA-11 and [¹⁷⁷Lu]-PSMA-617 ligands. Such discordance risks underestimating disease burden and excluding eligible patients. We present a case of metastatic castration-resistant prostate cancer (mCRPC) in whom a PSMA-negative adrenal lesion on PET exhibited significant LuPSMA uptake post-therapy and was subsequently confirmed as FDG-avid. Complementary stereotactic body radiotherapy (SBRT) achieved metabolic remission. This case highlights the clinical significance of integrating post-therapy LuPSMA imaging and FDG PET/CT with systemic treatment to ensure accurate disease characterization and personalized management of PSMA-/FDG+ lesions in advanced prostate cancer.
Medical subject headings
- Lutetium
- Prostatic Neoplasms, Castration-Resistant
- Dipeptides
- Heterocyclic Compounds, 1-Ring
- Positron Emission Tomography Computed Tomography
- Tomography, Emission-Computed, Single-Photon
- Edetic Acid
- Positron-Emission Tomography
- Heterocyclic Compounds